Drugs / AD1208
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06911333 | Mar 2025 → Jun 2029 expected | cancer | Avelos Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD1208 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06911333 ↗ |
| Action | Inhibit | “MASTL Inhibitor” NCT06911333 ↗ |
| Route | Oral | “AD1208 will be administered orally once or twice a day” NCT06911333 ↗ |
| Target | MASTL | “MASTL Inhibitor” NCT06911333 ↗ |